Abstract
In this study, we tested the efficacy and safety of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor (G-CSF) priming in patients who relapsed after haploidentical hematopoietic stem cell transplantation (HSCT). Twenty patients received DLI at a median of 177 days after HSCT. Eight patients survived in complete remission for a median of 1118 days. The 2-year probability of leukemia-free survival was 40%. Acute graft-versus-host disease (GVHD) grade 3-4 occurred in six patients after DLI. GVHD prophylaxis reduced the incidence of acute GVHD. Our primary data showed that G-CSF-primed DLI with GVHD prophylaxis was a potentially effective therapeutic option for patients who relapsed after haploidentical HSCT.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Child
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Disease-Free Survival
-
Etoposide / therapeutic use
-
Female
-
Graft vs Host Disease / epidemiology
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / prevention & control
-
Graft vs Leukemia Effect*
-
HLA Antigens / genetics
-
Haplotypes / genetics
-
Histocompatibility
-
Humans
-
Imatinib Mesylate
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Kaplan-Meier Estimate
-
Leukemia / drug therapy
-
Leukemia / surgery*
-
Lymphocyte Transfusion* / adverse effects
-
Male
-
Methotrexate / therapeutic use
-
Mitoxantrone / therapeutic use
-
Pancytopenia / epidemiology
-
Pancytopenia / etiology
-
Peripheral Blood Stem Cell Transplantation*
-
Piperazines / therapeutic use
-
Pyrimidines / therapeutic use
-
Recurrence
-
Remission Induction
-
Salvage Therapy*
-
Tissue Donors*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Benzamides
-
HLA Antigens
-
Immunosuppressive Agents
-
Piperazines
-
Pyrimidines
-
Cytarabine
-
Etoposide
-
Imatinib Mesylate
-
Mitoxantrone
-
Methotrexate
-
Daunorubicin